EVP, Research & Investments · Royalty Pharma plc · Class A Ordinary Shares
Side
SELL
Value
$805K
Shares
20.0K
Price
$40.26
Executed
Jan 23, 2026
Disclosed
Jan 26, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Jan 23 executedJan 26, 2026 disclosed
RPRX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+1 / 15
Routine: 6 prior trades recorded in this security
Frequency & clustering+5 / 15
1 other actor traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Urist Marshall filed this Form 4 reporting a open-market sale of RPRX on Jan 23, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
EVP, Research & Investments
Urist Marshallcik:0001838139
Issuer
Royalty Pharma plccik:0001802768
Revision history · 0
No field has changed since this record was first ingested.
